ReviewEndocrine, metabolic & immune disorders drug targets2009
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.
Review in Endocrine, metabolic & immune disorders drug targets, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 72 citations in OpenAlex.
- StackTTCA: a stacking ensemble learning-based framework for accurate and high-throughput identification of tumor T cell antigens.BMC bioinformatics · 2023Article
- Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy.International journal of molecular sciences · 2022Review
- Different In Vitro-Generated MUTZ-3-Derived Dendritic Cell Types Secrete Dexosomes with Distinct Phenotypes and Antigen Presentation Potencies.International journal of molecular sciences · 2022Article
- Tumor-Mediated Neutrophil Polarization and Therapeutic Implications.International journal of molecular sciences · 2022Review
- Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.Cytotechnology · 2018Review
- Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.Frontiers in immunology · 2018Review
- The Role of Forkhead Box 1 (FOXO1) in the Immune System: Dendritic Cells, T Cells, B Cells, and Hematopoietic Stem Cells.Critical reviews in immunology · 2017Review
- Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon.Molecular therapy. Nucleic acids · 2016Article
- Review
- Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.Journal of immunology research · 2015Review
- Specific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasis.PloS one · 2015Article
- Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.New journal of science · 2014Article
- Dendritic cell defects in the colorectal cancer.Human vaccines & immunotherapeutics · 2014Review
- Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?Oncoimmunology · 2013Review
- Article
- Specific Dioscorea Phytoextracts Enhance Potency of TCL-Loaded DC-Based Cancer Vaccines.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Article
- Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells.Gene therapy · 2012Article
- PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal.Journal of clinical & cellular immunology · 2012Article
- Dendritic cell-based vaccines: barriers and opportunities.Future oncology (London, England) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Tumour immunotherapy has become a treatment modality for cancer, harnessing the immune system to recognize and eradicate tumour cells specifically. It is based on the expression of tumour associated antigens (TAA) by the tumour cells and aims at the induction of TAA-specific effector T cell responses, whilst overruling various mechanisms that can hamper the anti-tumour immune response, e.g. regulatory T cells (Treg). (Re-) activation of effector T cells requires the completion of a carefully orchestrated series of specific steps. Particularly important is the provision of TAA presentation and strong stimulatory signals, delivered by co-stimulatory surface molecules and cytokines. These can only be delivered by professional antigen-presenting cells, in particular dendritic cells (DC). Therefore, DC need to be loaded with TAA and appropriately activated. It is not surprising that an extensive part of DC research has focused on the delivery of both TAA and activation signals to DC, developing a one step approach to obtain potent stimulatory DC. The simultaneous delivery of TAA and activation signals is therefore the topic of this review, emphasizing the role of DC in mediating T cell activation and how we can manipulate DC for the pill-pose of enhancing tumour immunotherapy. As we gain a better understanding of the molecular and cellular mechanisms that mediate induction of TAA-specific T cells, rational approaches for the activation of T cell responses can be developed for the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.